Cargando…
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343751/ https://www.ncbi.nlm.nih.gov/pubmed/30713597 http://dx.doi.org/10.18632/oncotarget.26528 |
| _version_ | 1783389321995223040 |
|---|---|
| author | Kolberg, Hans-Christian von Minckwitz, Gunter Hanes, Vladimir |
| author_facet | Kolberg, Hans-Christian von Minckwitz, Gunter Hanes, Vladimir |
| author_sort | Kolberg, Hans-Christian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6343751 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63437512019-02-01 Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars Kolberg, Hans-Christian von Minckwitz, Gunter Hanes, Vladimir Oncotarget Editorial Impact Journals LLC 2019-01-01 /pmc/articles/PMC6343751/ /pubmed/30713597 http://dx.doi.org/10.18632/oncotarget.26528 Text en Copyright: © 2019 Kolberg et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Editorial Kolberg, Hans-Christian von Minckwitz, Gunter Hanes, Vladimir Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title_full | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title_fullStr | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title_full_unstemmed | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title_short | Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars |
| title_sort | phase 3 lilac study sets standard for clinical evaluation of oncology biosimilars |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343751/ https://www.ncbi.nlm.nih.gov/pubmed/30713597 http://dx.doi.org/10.18632/oncotarget.26528 |
| work_keys_str_mv | AT kolberghanschristian phase3lilacstudysetsstandardforclinicalevaluationofoncologybiosimilars AT vonminckwitzgunter phase3lilacstudysetsstandardforclinicalevaluationofoncologybiosimilars AT hanesvladimir phase3lilacstudysetsstandardforclinicalevaluationofoncologybiosimilars |